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There are no officially approved therapies for metastatic pheochromocytomas apart from 
ultratrace 131I-MIBG therapy approved only in the United States. We have, therefore, 
investigated the anti-tumor potential of novel molecular-targeted approaches in murine 
pheochromocytoma cell lines (MPC/MTT), immortalized mouse chromaffin Sdhb-/- cells, 
3D-pheochromocytoma tumor models (MPC/MTT spheroids) and human 
pheochromocytoma primary cultures. We identified the specific PI3Kα inhibitor BYL719 
and the mTORC1 inhibitor everolimus as the most effective combination in all models. 
Single treatment with clinically relevant doses of BYL719 and everolimus significantly 
decreased MPC/MTT and Sdhb-/- cell viability. A targeted combination of both inhibitors 
synergistically reduced MPC and Sdhb-/- cell viability and showed an additive effect on MTT 
cells. In MPC/MTT spheroids, treatment with clinically relevant doses of BYL719 alone or in 
combination with everolimus was highly effective, leading to a significant shrinkage or even 
a complete collapse of the spheroids. We confirmed the synergism of clinically relevant doses 
of BYL719 plus everolimus in human pheochromocytoma primary cultures of individual 
patient tumors with BYL719 attenuating everolimus-induced AKT activation. We have thus 
established a method to assess molecular-targeted therapies in human pheochromocytoma 
cultures and identified a highly effective combination therapy. Our data pave the way to 
customized combination therapy to target individual patient tumors. 
1. Introduction 
Pheochromocytomas and paragangliomas (PCCs/PGLs) are rare neuroendocrine, 
catecholamine-producing tumors that originate from the adrenal medulla or extra-adrenal 
paraganglia. About 10% of PCCs and 35-40% of PGLs are metastatic (1-9). The prognosis of 
patients with metastatic PCC/PGL is poor, with a 5-year survival rate of 63% (10). Current 
therapeutic approaches for metastatic PCC/PGL, such as radionuclide therapy with 131I-
metaiodbenzylguanidine (MIBG), peptide receptor radionuclide therapy (PRRT) (11), or 
chemotherapy, are - apart from ultratrace 131I-MIBG approved only in the United States - not 
officially approved and are limited in their effectiveness, as recently reviewed (12). 
Therefore, novel therapeutic strategies are urgently needed. 
The standard chemotherapy regime for PCC/PGLs is CVD (cyclophosphamide, 
vincristine, dacarbazine). Inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase 
(PARP) have been demonstrated to potentiate DNA damaging effects of alkylating 
chemotherapeutic agents such as dacarbazine or temozolomide (13-15), both being 
metabolized to the same active metabolite (16). Therefore, combining standard chemotherapy 
with a PARP inhibitor might be a promising novel therapeutic approach. 
Another therapeutic approach is to define the aberrant molecular pathways in such tumors 
which can then be targeted by specific therapy. In around 30-40% of PCC/PGL patients 
germline mutations can be identified, with an equal number showing somatic mutations in 
more than 20 well-characterized susceptibility genes (17,18). These different mutations can 
be separated into three main molecular clusters (summarized in Fig. 1 and recently reviewed 
(19)):  
i) The pseudohypoxic signaling cluster (cluster-1)supple is related to mutations of genes encoding for 
proteins that are associated with significant regulation of the hypoxia signaling pathway; these include 
mutations in genes encoding for hypoxia-inducible factor-2α (HIF2A), Krebs cycle enzymes such as 
succinate dehydrogenase subunits (SDHx [SDHA, SDHB, SDHC, SDHD]), succinate dehydrogenase 
complex assembly factor-2 (SDHAF2), fumarate hydratase (FH), malate dehydrogenase 2 (MDH2), 
and isocitrate dehydrogenase 1 (IDH1). This pathway also includes mutations in von Hippel–Lindau 
tumor suppressor (VHL) and egl-9 prolyl hydroxylase-1 and -2 (EGLN1/2) genes. Such mutations 
promote HIF-α stabilization and accumulation resulting, amongst other effects, in increased 
angiogenesis via changes in vascular endothelial growth factor-1 and -2 receptors (VEGFR1/2) and 
platelet-derived growth factor-β receptor (PDGFR) transcription.  
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ii) The kinase signaling cluster (cluster-2) is related to mutations of genes encoding for proteins that belong 
to the phosphatidylinositol-3-kinase/mammalian target of rapamycin (PI3K/mTORC1) 
pathway/receptor kinase signaling, and comprises mutations in the rearranged-during-transfection 
(RET) proto-oncogene, neurofibromin 1 (NF1) tumor suppressor, H-RAS and K-RAS proto-oncogenes, 
transmembrane protein 127 (TMEM127) and Myc-associated factor X (MAX).  
 iii) Most recently, the Wnt signaling cluster (cluster-3) has been described as being of pathological 
significance. 
The multi-targeted receptor tyrosine kinase inhibitor (TKI) sunitinib has anti-angiogenic 
and anti-proliferative potential due to inhibition of VEGFR1/2, PDGFR, and RET, and has 
been approved for the treatment of renal cell carcinomas, pancreatic neuroendocrine tumors 
(NETs) and gastrointestinal stromal tumors. Sunitinib is currently being investigated in the 
first randomized placebo-controlled phase II clinical trial in PCC/PGL patients, in which 
recruitment has been completed (FIRST-MAPPP, NCT01371202).  
The mTORC1 inhibitor everolimus, currently used in the treatment of breast cancer, renal 
cell carcinoma and NETs, showed poor efficacy when used alone in PCC/PGLs (20). 
However, one SDHB-mutated patient who was treated with the combination of low doses of 
the mTORC1 inhibitor rapamycin and the TKI sunitinib showed maintained long-term 
disease control (21).  
In an in vivo breast cancer mouse model, the mTORC1 inhibitor everolimus has shown 
synergistic effects together with the PI3Kα inhibitor BYL719 (alpelisib) and overcame 
BYL719 resistance (22). The clinical phase III approval study SOLAR-1 investigating 
BYL719 in breast cancer patients has reached its final endpoints (23). Moreover, BYL719 
overcame everolimus resistance in a stably everolimus-resistant pancreatic NET cell line 
model (24). Therefore, combining different targeted drugs may strongly enhance their 
therapeutic potential and prevent the development of resistance.   
Based on these data, we have investigated the anti-tumor potential of a variety of both 
targeted and chemotherapeutic agents and their combinations, and their impact on cellular 
signaling pathways, in well-validated murine PCC cell line models and a murine Sdhb knock-
out (Sdhb-/-) cell line (the best available cell line models for highly aggressive SDHB-
mutated paragangliomas), 3D murine PCC spheroids and human PCC primary cultures, in 
order to identify novel therapeutic options.   
2. Materials and methods 
2.1 Cell lines 
Murine MPC (MPC 4/30/PRR) (25) and MTT (26) cell lines were cultured, as described 
previously (27) in DMEM/F12 (1:1) (Life Technologies, Karlsruhe, Germany), supplemented 
with 10% FBS (Biochrom, Berlin, Germany), 1% penicillin/streptomycin (Life Technologies) 
and 0.4% amphotericin B (Biochrom, Berlin, Germany) at 5% CO2 and 37°C. Cells were 
counted by an automated cell counter (Countess, Invitrogen, Germany). MPC/MTT cells 
were confirmed for species identity by cytochrome C oxidase I DNA barcoding, and for 
strain identity by comparing short tandem repeats (STRs) from these cell lines with STRs of 
identity-confirmed counterparts, as described previously (28). These analyses were 
performed by the DSMZ (Braunschweig, Germany). 
Immortalized mouse chromaffin cells both wild-type (WT) and Sdhb-/- (29) were 
cultured in DMEM Glutamax (Dulbecco Modified Eagle Medium, Gibco) with 10% FBS 
(Fetal bovine serum, Gibco) and 1% antibiotics (penicillin/streptomycin, Gibco) at 37°C in 
5% CO2.  
2.2 Inhibitors 
Everolimus, BYL719, sunitinib, temozolomide, niraparib (PARP inhibitor), cabozantinib (a 
TKI inhibiting c-met/VEGFR2/c-KIT/FLT3/RET/TIE2) and entinostat (a histone deacetylase 
(HDAC) 1/3 inhibitor) were purchased from Selleckchem (Munich, Germany). All drugs 
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were dissolved in DMSO (Sigma, D8418) and diluted in 0.2% bovine serum albumin 
(BSA)/PBS. DMSO was used as the vehicle (DMSO control) equal to the highest dose of 
each single experiment, and had no effect on cell viability up to concentrations of 0.2% 
(1:500) DMSO. 
2.3 Dose finding: Clinically relevant doses 
Treatment doses of 10-25nM everolimus were chosen since the plasma levels in patients on 
daily therapy with 10mg everolimus range between approximately 8nM (cmin after 2 weeks of 
daily exposure to 10mg everolimus) and 59nM (c2h after 12 weeks of daily exposure to 10mg 
everolimus) (30). 
Concentrations of 2.5µM-10µM BYL719 utilized in our experiments are also clinically 
relevant: in patients with advanced solid malignancies, median BYL719 plasma 
concentrations between 2µM and 11µM were found 2-8h post dose with one-month daily oral 
standard therapy with 300-450mg BYL719 (31). 
We used 0.5-2µM sunitinb in MPC/MTT cells and in human PCC cultures. 
Administration of 50mg sunitinib per day leads to plasma concentrations of 0.1–0.2µM (32). 
Thus, we only used a slightly higher dose as our starting concentration.  
We used 0.5-2µM cabozantinib in MPC/MTT cells and 1-10µM cabozantinib in human 
PCC cultures. Administration of 20-60mg of cabozantinib per day leads to plasma 
concentrations of 0.7-2.2µM (33).  
2.4 Human PCC primary cultures 
This study was approved by ENS@T – the European Network for the Study of Adrenal 
Tumors, and informed consent was obtained from each patient. Primary tumor tissues were 
isolated from adrenal glands of six different PCC patients, and lymph node/uterus metastases 
were isolated from one metastatic PGL patient (n=7). Specimens were taken immediately 
after surgery, and placed into Petri dishes filled with PBS. Tissue was separated into 0.5mm 
pieces. Diced tissue was resuspended in 10ml collagenase (Biochrom, Berlin, Germany) and 
incubated at 37°C for 60 min. Subsequently, 2ml pure FCS were added to inactivate the 
collagenase, and tumor tissue was centrifuged at 1100 rpm for 5 min. Supernatant was 
removed, and the pellet gently resuspended in erythrocyte lysis buffer. After 7 min. 
incubation, centrifugation was repeated, supernatant was removed and the pellet was 
resuspended in DMEM/F12 supplemented with 10% FCS, 1% penicillin/streptomycin and 
0.4% amphotericin B. Suspension was filtered through a 70µm sieve, cells were counted and 
seeded into 96-well or 6-well plates. After 3-5 days of incubation, cells were treated with 
everolimus, BYL719, sunitinib, temozolomide, niraparib, cabozantinib or entinostat. After 
48h or 72h, cell viability was analyzed. To confirm chromaffin cell origin, we used Western 
blot analysis of synaptophysin after 24h, as described below. 
2.5 Cell viability 
MPC/MTT cells were seeded into 96-well plates at densities of 2000 cells per well, grown for 
24h, and treated with different concentrations of sunitinib, BYL719 and cabozantinib, either 
alone or in combination with everolimus. Furthermore, cells were treated with niraparib alone 
or in combination with temozolomide or with entinostat alone. Metabolic activity was 
assessed by the “Cell Titer Blue®” cell viability assay (#G8081, Promega, Madison, WI, 
USA) after 48h, 72h and 120h of drug incubation. Cells were incubated for 4h with Cell Titer 
Blue® solution; fluorescence was measured at 560/590nm using a GLOMAX plate reader 
(Promega).  
2.6 Cell Cycle Analysis  
The cell cycle was analyzed (BD Accuri C6 Analysis), as previously described (24). For 
Flow Cytometric Analysis (FACS) analysis, cells were incubated for 24h with BYL719, 
everolimus and sunitinib alone or in combination. 
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2.7 Apoptosis  
Apoptosis was measured after 24h treatment with BYL719, everolimus and sunitinib, alone 
or in combination, using the Apo-One homogeneous caspase3/7-Assay kit (#G7790, 
Promega), as previously described (24). 
2.8 Cytotoxicity by crystal violet assay (CVA) 
2.5×103 cells/well were seeded into 48-well plates and treated for 72h (everolimus, BYL719, 
combination or vehicle). Crystal violet assay was then performed as previously described 
(34). Values were standardized to the vehicle absorbance at 24h and expressed as cell 
viability. Cell viability curves were established. Experiments were performed three times, in 
duplicates. 
2.9 Spheroid cultivation and treatment  
Generation and cultivation of MPC/MTT cell spheroids was conducted, as described 
previously (35,36). Four days after spheroid generation, spheroids were treated with sunitinib 
or BYL719 alone or in combination with everolimus. Afterwards, spheroid growth was 
monitored for 14 days (single treatment). During cultivation, medium was replaced every 
three to four days. Furthermore, a fractionated treatment regime was utilized by additional 
treatment of the spheroids on days 7, 11, and 14. 
2.10 Protein Extraction and Western Blot Analysis  
Cells were seeded into 10-cm plates and grown for 24h in complete medium before incubated 
with sunitinib and BYL719, either alone or in combination with everolimus, for 24h or 48h. 
Duplicate wells were used for each concentration of drug. Western blotting was conducted as 
described previously (37),using the following primary and secondary antibodies and their 
dilutions: pAktT (Ser473) (dilution: 1:20000) (RRID:AB_2315049) (38), AKT (dilution: 
1:5000) (RRID:AB_329827) (39), p4EBP1 (Ser65) (dilution: 1:2000) (RRID: AB_330947) 
(40), 4EBP1 (dilution: 1:1000) (RRID:AB_2097841) (41), p53 (dilution: 1:1000) (RRID: 
AB_10695803) (42), cyclin D1 (dilution: 1:1000) (RRID:AB_2259616) (43), cyclin D3 
(dilution: 1:2000) (RRID:AB_2070801) (44), pp70S6K (Thr389) (dilution: 1:1000) 
(RRID:AB_330944) (45), p70S6K (dilution: 1:5000) (RRID:AB_390722) (46), pS6 
(Ser240/244) (dilution: 1:200000) (RRID:AB_10694233) (47), S6 (dilution: 1:20000) 
(RRID:AB_331355) (48), pGSK3α/β (Ser21/9) (dilution: 1:5000) (RRID: AB_329830) (49), 
GSK3α/β (dilution: 1:1000) (RRID:AB_10547140) (50), CDK1/cdc2 (POH1) (dilution: 
1:1000) (RRID:AB_2074795) (51), Chk1 (2G1D5) (dilution: 1:000) (RRID:AB_2080320) 
(52) (Cell Signaling, Danvers, MA, USA), IRS-1 (dilution: 1:5000) (RRID:AB_2536328) 
(53), pIRS-1 (Ser312) (dilution: 1:5000) (RRID:AB_2533767) (54) (Invitrogen, Carlsbad, 
USA), actin (dilution: 1:10000) (RRID:AB_476744) (55) (Sigma-Aldrich, St. Louis, USA), 
and synaptophysin clone SY38 (dilution: 1:1000) (RRID:AB_95187) (56) (Merck-Millipore, 
Darmstadt, Germany). Western blot quantification was performed and a representative blot of 
three independent experiments is shown. 
2.11 Multi-gene panel next generation sequencing (NGS) 
Testing for disease-causing variants in PCC/PGL associated genes was performed by targeted 
next-generation sequencing (NGS), as described previously (57) using a custom designed 
multi-gene panel based on the TruSeq® Nano DNA Library Prep Kit (Illumina, San Diego, 
CA, USA).  
The panel comprises 84 genes including more than 20 genes associated with PCC/PGL 
(supplementary Table 1 (58)), and was shown to be suitable for analysis of blood and 
formalin fixed paraffin embedded (FFPE) or fresh frozen tumor tissue. DNA was isolated 
from formalin-fixed paraffin-embedded tumor tissue samples. Library preparation was done 
according to the manufacturer`s instructions and 150 nt paired-end sequencing was carried 
out with a minimum median coverage of 1000-fold on a NextSeq500 sequencer (Illumina). 
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Data analysis was performed using the Biomedical Genomics Workbench 5.0 (Qiagen), as 
described previously (59). Settings for variant calling in tumor tissue were adapted using a 
low frequency variant detection algorithm with a required minimum frequency of 5%, three 
reads supporting the variant and a required minimum coverage of ten reads.  
2.12 Statistical Analysis  
Results are displayed as mean ± standard deviation of the mean (SD) of at least three 
independent experiments. Each cell viability experiment consisted of at least six samples per 
concentration and incubation time. Cell viability in the MCP/MTT experiments was modeled 
via a linear mixed model with random effects for trial and fixed effects for substances and 
their interactions. For the human primary cultures we used a linear mixed model for the 
natural logarithm of the viability. Synergism was assessed, as described previously (60), and 
was confirmed when both single effects were significant, the interaction effect was 
significant, and all regression coefficients were negative. When both single effects were 
significant and the interaction effect was not significant, it was defined as an additive effect. 
For spheroid data, diameter of the spheroids was modeled via a quasi-Poisson mixed 
model with random effects for trial and spheroid. Temporal correlation was modeled via a 
continuous AR(1)-correlation structure. Besides the main effects, the model included a 
quadratic term for the day since starting and interactions between time and substances. All 
significance tests were performed within the respective model.  
Calculations were performed using R 3.5.1 (R Foundation for Statistical Computing, 
Vienna, Austria). Significance was assessed at p<0.05. Due to the exploratory character of 
this work, we did not adjust any p-values for multiple testing. 
3. Results 
3.1 MPC/MTT cells 
3.1.1 Cell viability after different drug treatments 
Treatment (120h) with clinically relevant doses of BYL719 (2.5µM/5µM) and everolimus 
(10nM), respectively, significantly diminished MPC/MTT cell viability compared to the 
control (Fig. 2); combination treatment with 5µM BYL719 and 10nM everolimus 
synergistically reduced MPC and additively MTT reduced cell viability (Fig. 2). 
Treatment with sunitinib (1µM/2µM) and everolimus (10nM), respectively, significantly 
reduced MPC/MTT cell viability compared to the control (Fig. 3). Combination treatment 
synergistically reduced MPC (1µM/2µM sunitinib plus 10nM everolimus) and MTT (2µM 
sunitinib plus 10nM everolimus) cell viability (Fig. 3). 
Cabozantinib (1µM/2µM) significantly reduced MPC/MTT cell viability (supplementary 
Fig. S1 (58)), but was not synergistic with everolimus (data not shown).  
Niraparib (0.5µM/1µM) and temozolomide (100µM/250µM) singly significantly reduced 
MPC/MTT cell viability compared to the control (Fig. 4). Combination of 0.5-1µM niraparib 
plus 100µM temozolomide, or 0.5µM niraparib plus 250µM temozolomide, synergistically 
diminished MTT, but not MPC, cell viability (Fig. 4). 
For all the following experiments in MPC/MTT cells and spheroids, we only investigated 
the most promising combinations (BYL719/everolimus and sunitinib/everolimus). 
3.1.2 Cell cycle and Apoptosis 
BYL719 (5µM), everolimus (10nM) and sunitinib (1µM/2µM) significantly increased the G1 
cell cycle phase in MPC cells, compared to the control (Fig. 5). In MTT cells everolimus 
(10nM) and sunitinib (1µM/2µM) significantly increased the G1 cell cycle phase. In both cell 
lines BYL719/everolimus or sunitinib/everolimus combination treatments further enhanced 
G1-phase cell cycle arrest, compared to single treatments (Fig. 5). Supplementary Fig. S2 
(58) shows the sub-G1-phase.  
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Apoptosis was investigated by caspase assay. In both cell lines significant apoptosis 
induction was observed after BYL719 treatment alone (2.5µM/5µM), after 
BYL719/everolimus combination treatment and – to a lesser extent – after the 
sunitinib/everolimus combination treatment (Figure 6). 
3.1.3 Western blot analysis  
Western blot results of MPC/MTT cells are shown in Figure 7. Western blot quantification is 
shown in supplementary Figure S3 (58). Everolimus is known to inhibit mTORC1/p70S6K 
and thereby activate AKT. Indeed, everolimus and each combination treatment inhibited 
p70S6K and S6 in MPC/MTT cells; 4EBP1, another mTORC1 effector, was inhibited by 
everolimus, BYL719 and each combination treatment. PI3K/AKTS473 was activated in 
response to everolimus, inhibited by BYL719, and unaffected by sunitinib. The 
BYL719/everolimus combination attenuated everolimus-induced PI3K/AKTS473 activation to 
the level of the untreated control. The sunitinib/everolimus combination did not effectively 
attenuate everolimus-induced PI3K/AKTS473 activation. Although most of the effects were 
seen at the highest doses tested, it is important to mention that these are still low clinically 
relevant doses (clinically relevant doses of BYL719 are 2-11µM and of everolimus 8-59nM). 
PI3K/AKT phosphorylates and thereby inhibits GSK3 (61). Persistent activation of PI3K 
leads to feed-back down-regulation of IRS-1, which may in turn lead to GSK3 dis-
inhibition/activation (62). GSK3α/β phosphorylation and thereby inhibition led to a 
significant decrease in NET cell viability (63). In this study BYL719 and everolimus alone 
led to GSK3 inhibition in MPC/MTT cells, while combination treatment even more strongly 
inhibited GSK3. The sunitinib/everolimus combination also led to GSK3 inhibition, 
compared to the control and single treatment in MTT cells, but inhibited GSK3β to a lesser 
extent than the BYL719/everolimus combination. BYL719 alone, everolimus alone and 
BYL719/everolimus combination treatment promoted IRS-1 up-regulation in MPC/MTT 
cells as a potential mechanism of GSK3 inhibition.  
Consistent with induction of G1 cell cycle arrest, Cyclin D1 and D3 decreased after 
BYL719/everolimus and sunitinib/everolimus combination treatments in MPC/MTT cells.  
3.2 Sdhb-/- immortalized mouse chromaffin cells (imCC) 
PCC/PGL patients carrying mutations in SDHB often show increased incidence of an early 
onset, increased metastatic risk, and thus a poor prognosis (64), and effective treatment 
strategies for these patients are missing. Therefore, we have investigated the impact of 
BYL719 (2.5µM), and everolimus (10nM) alone or in combination on immortalized mouse 
chromaffin cells (imCC) with and without expression of Sdhb. Sdhb-/- imCC carry a true 
knock-out of the Sdhb gene, leading to the absence of SDHB protein and complete inhibition 
of SDH activity (29). Both everolimus and BYL719 alone significantly reduced Sdhb-/- cell 
viability compared to the vehicle, with a synergistic effect of the combination at 72h (Fig. 8). 
Moreover, BYL719 treatment alone had a significantly stronger inhibitory effect on Sdhb-/- 
imCC viability compared to WT imCC viability after 48 and 72h treatment, but the 
combination treatment was no more effective in Sdhb-/- than in the WT cells after 72h 
treatment  (Fig. 8).  
3.3 MPC/MTT cell spheroids 
Tumor cell spheroids are characterized by an oxygen and nutrient gradient and provide an 
excellent in vitro model for drug screening with regard to their anti-tumor activity. 
Fractionated treatment with clinically relevant doses of BYL719 (5µM) led to a significant 
shrinkage of MPC/MTT spheroids, compared to the spheroid sizes at the beginning (day 4), 
and in several cases to complete spheroid collapse (day 16) (Fig. 9, supplementary 
Fig. S4A/D, S5A/D (58)). Fractionated treatment with clinically relevant doses of everolimus 
(25nM) significantly inhibited MPC/MTT spheroid growth (Fig. 9, supplementary Fig. 
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S4A/B/C, S5A/B/C (58)). These effects were enhanced by the BYL719/everolimus 
combination leading to a significant shrinkage or an early complete collapse of MPC/MTT 
spheroids in several experiments (day 9 and 14, respectively) (Fig. 9). While the DMSO 
control had an average diameter of 585±50.2µm (MPC) and 500±166.3µm (MTT) after 18 
days, fractionated treatment with 25nM everolimus plus 5µM BYL719 led to a significantly 
smaller average spheroid diameter of 59.5±68.8µm (MPC) and 62.7±42.3µm (MTT), 
respectively. Fractionated treatment with sunitinib only slowed spheroid growth down 
(supplementary Fig. S4B/C, S5B/C (58)). In MPC spheroids, sunitinib enhanced the efficacy 
of everolimus (supplementary Fig. S4B/C/F/G (58)), but not in MTT spheroids after 
fractionated treatment (supplementary Fig. S4B/C (58)). Fractionated treatment was more 
effective than single treatment. No spheroid re-growth was seen after BYL719 single 
treatment. 
3.4 Human primary cultures  
3.4.1 Clinical, histological and genetic characteristics (Table 1) 
We were able to generate primary cultures from seven different PCC/PGL patients, and 
confirmed tumor identity by detecting synaptophysin as a well-established PC /PGL marker 
[30]. 
Tumors from patients 1, 2, 4 and 6 showed certain criteria associated with an adverse 
prognosis including capsule invasion, vascular invasion, a size of >5 cm, or a Ki-67 of 5% 
(Table 1), although they were not metastatic. Patient 7 had a metastatic PGL.  
Targeted NGS (Table 1) showed disease-causing NF1 mutations in tumors of patients 2 
and 3, in line with cluster 2 tumors. These were likely somatic mutations; in neither patient 
was germline testing available, but neither showed any clinical stigmata of 
neurofibromatosis. However, to completely exclude the possibility of a hereditary PPGL 
syndrome, pathogenic variants identified in tumor tissue would need to be analyzed in 
corresponding blood samples as well. 
In tumor tissue from patient 7, we identified a missense variant of unknown significance 
(VUS) in the Tet Methylcytosine Dioxygenase (TET1) gene, a demethylase involved in 
epigenetic regulation and gene activation. In the tumor tissues from patients 1 and 4, no 
known disease-causing susceptibility mutation was identified by NGS. NGS was not 
performed on tumor tissues from patients 5 and 6.   
3.4.2 Primary cell culture viability after different drug treatments 
We have statistically combined all human tumor cultures in which combination treatments 
were tested (tumor cultures from six different patients, n=6).  
In all combination-treated human primary cultures (n=6), clinically relevant doses of 
BYL719 (2.5µM/5µM) and everolimus (10nM) significantly reduced viability, and the 
combination of 5µM BYL719 and 10nM everolimus was highly effective and synergistic 
(P<0.05) (Fig. 10).  
Sunitinib (2µM) significantly decreased primary culture viability, but was not synergistic 
with everolimus (Fig. 10).  
We could not test combination treatments in the primary cultures from patient 7 as there 
was insufficient tissue material. Sunitinib (1-8µM) and clinically relevant doses of BYL719 
(2.5-10µM) separately decreased viability of the primary cultures from patient 7 
(supplementary Fig. S6 (58)). 
Furthermore, we were able to test entinostat (1-10µM), cabozantinib (1-10µM), niraparib 
(5-10µM) and temozolomide (100-250µM) in primary cultures from five different PCC 
patients. Entinostat (1-10µM), cabozantinib (1-10µM) and niraparib (5-10µM) significantly 
decreased primary culture viability, but temozolomide had no effect (Fig. 11).  
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3.4.3 Western blot analysis  
We had sufficient human primary culture material from patients 2, 3 and 5 for performing 
detailed Western blot analysis of these primary cultures; the results are shown in Fig. 12. 
Western blot quantification of the treatments performed identically in all three primary 
cultures (control DMSO, 10nM everolimus, 2µM BYL719, BYL719/everolimus 
combination) is shown in supplementary Fig. S7 (58). Supplementary Table 2 (58) shows all 
the values of the Western blot quantification of all primary culture Western blots. The 
mTORC1 effector proteins p70S6K and S6 were strongly inhibited by everolimus and by 
each combination treatment at 24h; 4EBP1, another mTORC1 effector protein, was inhibited 
by everolimus and the BYL719/everolimus combination treatment. AKTS473 was activated in 
response to everolimus, and this activation was attenuated by addition of BYL719 in the 
primary cultures from patients 3 and 5. In contrast to the mouse cell lines, inhibition of GSK3 
by BYL719 or by combination treatments could not be shown, possibly due to a shorter 
treatment time of 24h. However, after a longer incubation time of 48h, the protein 
concentration of the primary cultures was too low for Western blot detection. P53 was 
moderately down-regulated by the everolimus/BYL719 combination. Consistent with a G1-
phase cell cycle arrest, combination treatments were associated with down-regulation of the 
cell cycle promoting markers cyclin D3, CDK1 cdc2 (patient 3) and chk1 (patients 3, 5).  
4. Discussion 
We have shown that targeted combination treatment with clinically relevant doses of the 
PI3Kα inhibitor BYL719 and the mTORC1 inhibitor everolimus exhibited strong synergistic 
anti-tumor potential in PCC cell lines and especially Sdhb-/- cells, and in human PCC 
primary cultures. In MPC/MTT 3D-spheroids, this combination treatment led to dramatic 
spheroid shrinkage or a complete spheroid collapse in several experiments. The 
BYL719/everolimus combination was the most effective treatment we have ever tested in 
PCC spheroids.  
Everolimus has been approved for the treatment of NETs in many countries (65-67). 
Similarly to PCC/PGL with increased PI3K/AKT/mTORC1 activation (68), 
gastroenteropancreatic NETs also show frequent PI3K/AKT/mTORC1 over-activation 
(69,70). However, everolimus alone showed disappointing results in a small PCC/PGL 
patient study (20). Compensatory IRS-1/PI3K/AKT dis-inhibition/activation in response to 
mTORC1/p70S6K inhibition is the known short-term mechanism of everolimus resistance 
(71-75). Indeed, we found strong everolimus-induced PI3K/AKT activation in PCC cell lines 
and human primary cultures. In different NET cell lines the PI3Kα inhibitor BYL719 showed 
synergism with everolimus at clinically relevant doses (24,76) and overcame long-term 
everolimus resistance in human pancreatic NET cells (24). In a breast cancer model, 
everolimus also acted synergistically with BYL719, and delayed the development of 
resistance to BYL719 in vitro and in vivo (22). Consistently, we showed in our murine PCC 
cell lines and two different human PCC cultures that addition of BYL719 attenuated 
everolimus-induced AKT activation, which may essentially contribute to the synergism of 
both drugs. As also observed in human NET cells (24,76), BYL719/everolimus combination 
treatment led to synergistic inhibition of GSK3 in PCC cell lines – possibly as a consequence 
of IRS-1 up-regulation. IRS-1 has previously been shown to inhibit GSK3 via different 
signaling pathways (61,77,78), and GSK3 inhibition has shown anti-tumor potential in human 
NET cell lines (63).  
In our murine cell lines, the BYL719/everolimus combination induced a significant G1-
phase cell cycle arrest that was more prominent than in each single-drug treatment. 
Consistently, the BYL719/everolimus combination led to cyclin D1/D3 down-regulation in 
PCC cell lines and human primary cultures.  
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In contrast to other PI3K inhibitors, such as NVP-BEZ235 or BKM120, BYL719 is most 
likely to become clinically available. The phase III approval study SOLAR-1 evaluating 
BYL719 (alpelisib) in metastatic breast cancer has reached its final endpoints (23). Another 
phase IB trial is evaluating the safety of BYL719 (alpelisib) plus everolimus in advanced 
breast, renal cell and pancreatic cancer, including pancreatic NETs (NCT02077933).  
Sunitinib is being evaluated in the first randomized, prospective, placebo-controlled 
clinical phase II trial in PCC/PGL (FIRST-MAPPP, NCT01371202), which has completed 
recruitment. A synergistic effect of sunitinib and everolimus was shown in MPC/MTT cell 
lines at doses exceeding clinical relevance, but not in human primary cultures. This may be in 
part due to additional anti-angiogenic activity of sunitinib in vivo, which cannot be mimicked 
by cell culture. However, BYL719/everolimus combination treatment seems to be more 
promising, as compared to sunitinib/everolimus in vitro. Nevertheless, one case in the 
literature notes an SDHB-mutated patient who received the mTORC1 inhibitor rapamycin in 
combination with sunitinib and experienced long-term disease control (21).  
The combination of niraparib with temozolomide was synergistic in the MTT cells, 
although not in human primary cultures. PARP inhibition by niraparib suppresses DNA 
repair, and sensitizes tumors to alkylating DNA-damaging agents (14,79,80) thus synergizing 
with temozolomide in the murine PCC cell lines. Consistent with this, in an allograft PCC 
mouse model, a PARP inhibitor sensitized PCCs to temozolomide (15). However, 
temozolomide showed an absence of efficacy in human primary cultures, while niraparib and 
also entinostat were effective in primary cultures. This implicates fundamental differences of 
drug effects between murine cell lines and human primary cultures, rendering additional 
confirmatory drug testing in human primary cultures even more important. 
Cabozantinib showed significant efficacy in PCC cell lines and human primary cultures at 
clinically relevant doses, but no synergism with everolimus. The PCC cell lines and human 
primary cultures displayed a weaker response to cabozantinib alone, as compared to 
everolimus/BYL719 combination treatment. Our data suggest that dual PI3K/mTORC1 
inhibition might be more effective at lower doses with less toxicity. As a next step, we will 
investigate the most promising combination of everolimus/BYL719 in vivo in a suitable PCC 
allograft model.  
The success of the different molecular-targeted therapies alone and in combination 
essentially depends on the individual molecular aberrations of each tumor, as shown in other 
tumor types (81). For example, the tumors from patients 2 and 3 are both associated with NF1 
mutations leading to MEK/RAS/ERK and mTORC1 over-activation (82-84). Accordingly, 
both tumor cultures responded well to both mTORC1 and PI3Kα inhibition by everolimus 
and BYL719, respectively, and especially to the combination, with attenuation of everolimus-
induced AKT activation by BYL719. This suggests that amongst others NF1-mutated tumors 
– frequently present amongst sporadic PCCs (85) – should respond to these targeted drugs. In 
the PGL of patient 7, who had an unusual metastatic phenotype, no disease-causing variants 
were identified in any of the known PCC/PGL susceptibility genes; however, a VUS in TET1, 
a DNA demethylase, was found, which presents a potential candidate gene that needs further 
investigation in the future.  
4.1 Conclusions 
We have established a method to investigate molecular-targeted agents in human PCC 
primary cultures of individual patient tumors and we have correlated drug efficacy with 
signaling pathway alterations. The established protocol for ex vivo treatment of human 
PCC/PGL primary cultures with different molecular-targeted drugs allows screening for 
appropriate treatment approaches for each individual patient. In addition, we identified dual 
mTORC1/PI3Kα inhibition by the everolimus/BYL719 combination treatment as clinically 
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relevant, highly effective synergistic targeted therapy in all the PCC models investigated, 
including human tumor cultures. 
Supplementary data 
https://EMDS-
NAS.quickconnect.to/d/s/496975158882345550/sUrm8NYh5szKPD5NacKzaoXM18OrpRi
V-TyKA5VWc5QY_ 
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Figure 1. Overview: Cluster-1, -2 and -3, with molecular-targeted therapeutic options: 
Cluster-1: The pseudo-hypoxic signaling cluster includes mutations in genes encoding for 
hypoxia-inducible factor 2-alpha (HIF2A), Krebs-cycle enzymes such as succinate 
dehydrogenase subunits (SDHx [SDHA, SDHB, SDHC, SDHD]), succinate dehydrogenase 
complex assembly factor-2 (SDHAF2), fumarate hydratase (FH), malate dehydrogenase 2 
(MDH2), and isocitrate dehydrogenase (IDH), and including von Hippel–Lindau tumor 
suppressor (VHL) and egl-9 prolyl hydroxylase 1 and 2 (EGLN1/2). Cluster-2: The kinase 
signaling cluster comprises mutations in the rearranged-during-transfection (RET) proto-
oncogene, neurofibromin 1 (NF1) tumor suppressor, H-RAS and K-RAS proto-oncogenes, 
transmembrane protein 127 (TMEM127) and Myc-associated factor X (MAX). Receptor 
tyrosine kinases (amongst others RET, vascular endothelial cell growth factor (VEGFR), c-
met) activate insulin receptor substrate 1 (IRS-1) which recruits the phosphatidylinositol-3-
kinase (PI3K). PI3K activates AKT, which inhibits tuberous sclerosis proteins 1/2 (TSC1/2) 
leading to disinhibition/activation of the mammalian target of rapamycin (mTORC1); 
mTORC1 phosphorylates and activates various proteins including p70S6 kinase (p70S6K), 
by which p70S6 is phosphorylated. Activated p70S6 promotes cell growth, proliferation, cell 
survival, and leads amongst other effects to the protein synthesis of HIF-1α, which favors 
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angiogenesis [VEGF/platelet-derived growth factor (PDGF) transcription amongst others], 
invasion and metastasis under hypoxic or pseudo-hypoxic conditions. AKT also inhibits 
glycogen synthase kinase 3 (GSK3). Persistent activation of PI3K leads to feed-back down-
regulation of IRS-1, which in turn may lead to GSK3 dis-inhibition/activation. The 
RAS/RAF/ERK-pathway is also activated by tyrosine kinases (amongst others RET) and 
activates mTORC1. NF1 mutations lead to disinhibition/activation of RAS. TMEM127 
mutations lead to disinhibition/activation of mTORC1. The tumor suppressor MAX 
antagonizes Myc-dependent cell survival, proliferation and angiogenesis: mutations lead to 
increased cell proliferation and angiogenesis. Cluster-3: The Wnt signaling cluster comprises 
somatic mutations in cold shock domain containing E1 (CSDE1) and the mastermind like 
transcriptional coactivator 3 (MAML3) fusion genes. ⊘ Pheochromocytoma promoting loss 
of function mutation of a tumor suppressor gene. Pheochromocytoma promoting gain of 
function mutation of a proto-oncogene.   Increase/up-regulation. ⏊ Inhibition. ↘ Activation 
Figure 2. Significant MPC/MTT cell viability reduction by clinically relevant doses of 
BYL719, everolimus and by the combination of both after 120h. The BYL719/everolimus 
combination treatment was statistically synergistic (@) in MPC cells and additive in MTT 
cells. The arithmetic means and standard deviation of at least three independent experiments 
are shown. Statistically significant differences in comparison to the DMSO control are 
shown, considering p<0.05 as significant (*). 
Figure 3. Significant MPC/MTT cell viability reduction by sunitinib, everolimus and by the 
combination of both after 120h. Sunitinib/everolimus combination treatment was statistically 
synergistic (@) in both cell lines. The arithmetic means and standard deviation of at least 
three independent experiments are shown. Statistically significant differences in comparison 
to the DMSO control are shown, considering p<0.05 as significant (*).  
Figure 4. Significant MPC/MTT cell viability reduction by niraparib, temozolomide and by 
the combination of both after 120h. The niraparib/temozolomide combination was 
statistically synergistic (@) in MTT cells, but not in MPC cells. Statistically significant 
differences in comparison to the DMSO control are shown, considering p<0.05 as significant 
(*). 
Figure 5. Cell cycle analysis via FACS: Significant induction of a G1-phase cell cycle arrest 
in MPC cells by BYL719, everolimus or sunitinib alone and – even stronger – by the 
BYL719/everolimus and sunitinib/everolimus combination treatments at 24h treatment. 
Significant induction of a G1-phase cell cycle arrest in MTT cells by everolimus (10nM) and 
sunitinib (1µM/2µM) and – even stronger – by the BYL719/everolimus and 
sunitinib/everolimus combination treatment at 24h treatment. The arithmetic means and 
standard deviation of at least three independent experiments are shown. Statistically 
significant differences in comparison to the DMSO control are shown, considering p<0.05 as 
significant (*). 
Figure 6. Mean caspase-3/-7 activity in percent ± standard deviation in MPC/MTT cell lines 
after 24h of incubation with different drugs. In both cell lines significant apoptosis induction 
was observed after BYL719 treatment alone, after tBYL719/everolimus combination 
treatment, and - to a lesser extent - after sunitinib/everolimus combination treatment. The 
arithmetic means and standard deviation of at least three independent experiments are shown. 
Statistically significant differences in comparison to the DMSO control are shown, 
considering p<0.05 as significant (*). 
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Figure 7. Western blot analysis of MPC/MTT cell lines after 24h or 48h of incubation with 
different drugs: Inhibition of p70S6K, S6, 4EBP1 and GSK3 signaling, attenuation of 
everolimus-induced AKT activation, IRS-1 up-regulation and cyclin D1/D3 down-regulation 
after BYL719/everolimus combination treatment. A representative blot of three 
independently performed experiments is shown.  
Figure 8. Significant reduction of cell viability after BYL719 and everolimus treatment in 
immortalized mouse chromaffin wild-type (WT) and Sdhb-/- cells at 48h and 72h with a 
synergistic effect (@) of the combination in both cell lines at 72h, and a significantly stronger 
effect of BYL719 alone in the Sdhb-/- compared to the WT cells. Significant difference 
between WT and Sdhb-/- (∆). Statistically significant differences in comparison to the DMSO 
control are shown, considering p<0.05 as significant (*). 
Figure 9. Significant MPC/MTT spheroid shrinkage or complete spheroid collapse after 
fractionated treatment with 5µM BYL719, even stronger shrinkage, as compared to BYL719 
alone, or an early complete collapse of the spheroids in several experiments after fractionated 
treatment with the BYL719/everolimus combination, and spheroid growth inhibition after 
fractionated treatment with 25nM everolimus. Spheroids were treated with different 
concentrations of BYL719 and everolimus after completed spheroid formation (day 4) and, in 
addition, on day 7, 11, and 14 (fractionated treatment). Growth was monitored over a time 
period of 18 days. The arithmetic means and all single values of each experiment of at least 
three independent experiments are shown. Statistically significant different results in 
comparison to the DMSO control are shown, considering p<0.05 as significant (*). 
Figure 10. Significant reduction of human PCC primary culture viability (n=6) by clinically 
relevant doses of BYL719, everolimus and the combination of BYL719 plus everolimus at 
72h treatment, showing a synergistic effect (@) of 5µM BYL719 plus 10nM everolimus. 
Moreover, a significant reduction of human PCC primary culture viability (n=6) by sunitinib 
and the combination of sunitinib plus everolimus is seen at 72h. Sunitinib and everolimus did 
not act synergistically. The arithmetic means and all single values of six human PCC cultures 
from six different patients are shown. Statistically significant different results in comparison 
to the DMSO control are shown, considering *p<0.05 as significant (*). 
Figure 11. Significant reduction of human PCC primary culture viability (n=5) by 
cabozantinib, entinostat and niraparib, but not temozolomide, at 72h treatment. The 
arithmetic means and all single values of five human PCC primary cultures from five 
different patients are shown. Statistically significant different results in comparison to the 
DMSO control are shown, considering p<0.05 as significant (*). 
Figure 12. Western blot analysis of the human primary cultures from patients 2, 3 and 5 after 
24h of incubation with different drugs. There was strong synaptophysin expression in all 
primary cultures.  There was strong inhibition of mTORC1/p70S6K and 4EBP1 signaling by 
everolimus and all combination treatments, attenuation of everolimus-induced AKT 
activation by the combination treatment in the primary cultures from patients 3 and 5, and 
down-regulation of cyclin D3, CDK1 cdc2 (patient 3), chk1 (patients 3, 5) and p53 by the 
combination treatment. GSK3 showed no clear differences – most likely due to suboptimal 
incubation times.  
Table 1. Clinical and histological characteristics of the human  PCC/PGL primary cultures 
from 7 different patients 
 Age Sex Tumor metastatic Histology and criteria of Ki-67 Next Generation 
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malignancy (%) Sequencing (NGS) of the 
tumors 
Patient 1 82 M Adrenal pheochromocytoma no Tumor size: 1.5 cm, capsule invasion 1-2 
No known susceptibility 
mutation 
Patient 2 50 M Adrenal pheochromocytoma no Tumor size: 12.9 cm, nuclear pleomorphism 1-2 NF1 mutation 
Patient 3 73 F Adrenal pheochromocytoma no Tumor size: 3.9 cm, nuclear 
and cell pleomorphism 2 NF1 mutation 
Patient 4 26 M Adrenal pheochromocytoma no 
Tumor size: 3.2 cm, vascular 
invasion, anisonucleosis, cell 
inclusions 
5 No known susceptibility 
mutation 
Patient 5 65 M Adrenal pheochromocytoma no Tumor size: 5 cm <1 not assessed 
Patient 6 60 M Adrenal pheochromocytoma no Tumor size: 5.5 cm, capsule invasion, vascular invasion <1 not assessed 
Patient 7 30 F 
Uterus metastasis yes Tumor size: 5.3 cm 20 Variance of unknown 
significance (VUS) in TET1 Lymph node metastasis yes Tumor size: 2.5 cm 20 
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Figure 1 Loss of function mutation
Gain of function mutation
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@ Synergistic effect of BYL719/everolimus in MPC cells
* Significant decrease of cell viability compared to control DMSO
Figure 2
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Figure 3
@ Synergistic effect of sunitinib/everolimus in MPC/MTT cells
* Significant decrease of cell viability compared to control DMSO
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Figure 4
@ Synergistic effect of temozolomide/niraparib in MTT cells
* Significant decrease of cell viability compared to control DMSO
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Figure 5
* Significant difference of the percentage of cells in the respective cell cycle phase between control DMSO and different treatments
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Figure 6
* Significant increase of caspase activity compared to control DMSO
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Figure 7
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Cell viability in Sdhb-/- imCC and WT imCC
Figure 8
@ Synergistic effect of BYL719/everolimus
* Significant decrease of cell viability compared to control DMSO
ѐ Significant difference between WT and Sdhb-/-
*
control DMSO 10 nM everolimus 2.5 µM BYL719 combination
*
* *
*
*
@
Sdhb-/-
WT
ѐ
ѐ
control DMSO 10 nM everolimus 2.5 µM BYL719 combination
*
*
*
*
*
@
*
@
Sdhb-/-
WT
ѐ
ѐ
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25 nM 
everolimus +
5 µM BYL719
5 µM 
BYL719
MPC cell spheroids MTT cell spheroids
DMSO
25 nM 
everolimus
25 nM 
everolimus +
5 µM BYL719
5 µM 
BYL719
Figure 9
* Significant decrease of spheroid size compared to control DMSO
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Figure 10
@ Synergistic effect of everolimus/BYL719 in human PCC primary cells
* Significant decrease of cell viability compared to control DMSO
BYL719/everolimus and sunitinib/everolimus treatment 
in human PCC primary cultures (n=6)
* * * * * *@
* * * * * *
* * *
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Figure 11
* Significant decrease of cell viability compared to control DMSO
Cabozantinib, entinostat, niraparib and temozolomide 
treatment in human PCC primary cultures (n=5)
* ** * *
*
**
**
*
*
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Figure 12
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